Engineered human hepatocyte organoids enable CRISPR-based target discovery and drug screening for steatosis

Delilah Hendriks; Jos F Brouwers; Karien Hamer; Maarten H Geurts; Léa Luciana; Simone Massalini; Carmen López-Iglesias; Peter J Peters; Maria J Rodríguez-Colman; Susana Chuva de Sousa Lopes; Benedetta Artegiani; Hans Clevers

doi:10.1038/s41587-023-01680-4

Engineered human hepatocyte organoids enable CRISPR-based target discovery and drug screening for steatosis

Delilah Hendriks, Jos F Brouwers, Karien Hamer, Maarten H Geurts, Léa Luciana, Simone Massalini, Carmen López-Iglesias, Peter J Peters, Maria J Rodríguez-Colman, Susana Chuva de Sousa Lopes, Benedetta Artegiani, Hans Clevers

Hubrecht Institute

Research output: Contribution to journal/periodical › Article › Scientific › peer-review

102 Citations (Scopus)

Abstract

The lack of registered drugs for nonalcoholic fatty liver disease (NAFLD) is partly due to the paucity of human-relevant models for target discovery and compound screening. Here we use human fetal hepatocyte organoids to model the first stage of NAFLD, steatosis, representing three different triggers: free fatty acid loading, interindividual genetic variability (PNPLA3 I148M) and monogenic lipid disorders (APOB and MTTP mutations). Screening of drug candidates revealed compounds effective at resolving steatosis. Mechanistic evaluation of effective drugs uncovered repression of de novo lipogenesis as the convergent molecular pathway. We present FatTracer, a CRISPR screening platform to identify steatosis modulators and putative targets using APOB-/- and MTTP-/- organoids. From a screen targeting 35 genes implicated in lipid metabolism and/or NAFLD risk, FADS2 (fatty acid desaturase 2) emerged as an important determinant of hepatic steatosis. Enhancement of FADS2 expression increases polyunsaturated fatty acid abundancy which, in turn, reduces de novo lipogenesis. These organoid models facilitate study of steatosis etiology and drug targets.

Original language	English
Pages (from-to)	1567-1581
Number of pages	15
Journal	Nature Biotechnology
Volume	41
Issue number	11
DOIs	https://doi.org/10.1038/s41587-023-01680-4
Publication status	Published - Nov 2023

Keywords

Humans
Non-alcoholic Fatty Liver Disease/drug therapy
Drug Evaluation, Preclinical
Hepatocytes/metabolism
Lipid Metabolism
Apolipoproteins B/metabolism
Liver/metabolism

Access to Document

10.1038/s41587-023-01680-4

Cite this

Hendriks, D., Brouwers, J. F., Hamer, K., Geurts, M. H., Luciana, L., Massalini, S., López-Iglesias, C., Peters, P. J., Rodríguez-Colman, M. J., Chuva de Sousa Lopes, S., Artegiani, B., & Clevers, H. (2023). Engineered human hepatocyte organoids enable CRISPR-based target discovery and drug screening for steatosis. Nature Biotechnology, 41(11), 1567-1581. https://doi.org/10.1038/s41587-023-01680-4

@article{8c7d76a5e06d431f905b525d80883c77,

title = "Engineered human hepatocyte organoids enable CRISPR-based target discovery and drug screening for steatosis",

abstract = "The lack of registered drugs for nonalcoholic fatty liver disease (NAFLD) is partly due to the paucity of human-relevant models for target discovery and compound screening. Here we use human fetal hepatocyte organoids to model the first stage of NAFLD, steatosis, representing three different triggers: free fatty acid loading, interindividual genetic variability (PNPLA3 I148M) and monogenic lipid disorders (APOB and MTTP mutations). Screening of drug candidates revealed compounds effective at resolving steatosis. Mechanistic evaluation of effective drugs uncovered repression of de novo lipogenesis as the convergent molecular pathway. We present FatTracer, a CRISPR screening platform to identify steatosis modulators and putative targets using APOB-/- and MTTP-/- organoids. From a screen targeting 35 genes implicated in lipid metabolism and/or NAFLD risk, FADS2 (fatty acid desaturase 2) emerged as an important determinant of hepatic steatosis. Enhancement of FADS2 expression increases polyunsaturated fatty acid abundancy which, in turn, reduces de novo lipogenesis. These organoid models facilitate study of steatosis etiology and drug targets.",

keywords = "Humans, Non-alcoholic Fatty Liver Disease/drug therapy, Drug Evaluation, Preclinical, Hepatocytes/metabolism, Lipid Metabolism, Apolipoproteins B/metabolism, Liver/metabolism",

author = "Delilah Hendriks and Brouwers, {Jos F} and Karien Hamer and Geurts, {Maarten H} and L{\'e}a Luciana and Simone Massalini and Carmen L{\'o}pez-Iglesias and Peters, {Peter J} and Rodr{\'i}guez-Colman, {Maria J} and {Chuva de Sousa Lopes}, Susana and Benedetta Artegiani and Hans Clevers",

note = "{\textcopyright} 2023. The Author(s).",

year = "2023",

month = nov,

doi = "10.1038/s41587-023-01680-4",

language = "English",

volume = "41",

pages = "1567--1581",

journal = "Nature Biotechnology",

issn = "1087-0156",

publisher = "Nature Publishing Group",

number = "11",

}

Hendriks, D, Brouwers, JF, Hamer, K, Geurts, MH, Luciana, L, Massalini, S, López-Iglesias, C, Peters, PJ, Rodríguez-Colman, MJ, Chuva de Sousa Lopes, S, Artegiani, B & Clevers, H 2023, 'Engineered human hepatocyte organoids enable CRISPR-based target discovery and drug screening for steatosis', Nature Biotechnology, vol. 41, no. 11, pp. 1567-1581. https://doi.org/10.1038/s41587-023-01680-4

TY - JOUR

T1 - Engineered human hepatocyte organoids enable CRISPR-based target discovery and drug screening for steatosis

AU - Hendriks, Delilah

AU - Brouwers, Jos F

AU - Hamer, Karien

AU - Geurts, Maarten H

AU - Luciana, Léa

AU - Massalini, Simone

AU - López-Iglesias, Carmen

AU - Peters, Peter J

AU - Rodríguez-Colman, Maria J

AU - Chuva de Sousa Lopes, Susana

AU - Artegiani, Benedetta

AU - Clevers, Hans

PY - 2023/11

Y1 - 2023/11

N2 - The lack of registered drugs for nonalcoholic fatty liver disease (NAFLD) is partly due to the paucity of human-relevant models for target discovery and compound screening. Here we use human fetal hepatocyte organoids to model the first stage of NAFLD, steatosis, representing three different triggers: free fatty acid loading, interindividual genetic variability (PNPLA3 I148M) and monogenic lipid disorders (APOB and MTTP mutations). Screening of drug candidates revealed compounds effective at resolving steatosis. Mechanistic evaluation of effective drugs uncovered repression of de novo lipogenesis as the convergent molecular pathway. We present FatTracer, a CRISPR screening platform to identify steatosis modulators and putative targets using APOB-/- and MTTP-/- organoids. From a screen targeting 35 genes implicated in lipid metabolism and/or NAFLD risk, FADS2 (fatty acid desaturase 2) emerged as an important determinant of hepatic steatosis. Enhancement of FADS2 expression increases polyunsaturated fatty acid abundancy which, in turn, reduces de novo lipogenesis. These organoid models facilitate study of steatosis etiology and drug targets.

AB - The lack of registered drugs for nonalcoholic fatty liver disease (NAFLD) is partly due to the paucity of human-relevant models for target discovery and compound screening. Here we use human fetal hepatocyte organoids to model the first stage of NAFLD, steatosis, representing three different triggers: free fatty acid loading, interindividual genetic variability (PNPLA3 I148M) and monogenic lipid disorders (APOB and MTTP mutations). Screening of drug candidates revealed compounds effective at resolving steatosis. Mechanistic evaluation of effective drugs uncovered repression of de novo lipogenesis as the convergent molecular pathway. We present FatTracer, a CRISPR screening platform to identify steatosis modulators and putative targets using APOB-/- and MTTP-/- organoids. From a screen targeting 35 genes implicated in lipid metabolism and/or NAFLD risk, FADS2 (fatty acid desaturase 2) emerged as an important determinant of hepatic steatosis. Enhancement of FADS2 expression increases polyunsaturated fatty acid abundancy which, in turn, reduces de novo lipogenesis. These organoid models facilitate study of steatosis etiology and drug targets.

KW - Humans

KW - Non-alcoholic Fatty Liver Disease/drug therapy

KW - Drug Evaluation, Preclinical

KW - Hepatocytes/metabolism

KW - Lipid Metabolism

KW - Apolipoproteins B/metabolism

KW - Liver/metabolism

U2 - 10.1038/s41587-023-01680-4

DO - 10.1038/s41587-023-01680-4

M3 - Article

C2 - 36823355

SN - 1087-0156

VL - 41

SP - 1567

EP - 1581

JO - Nature Biotechnology

JF - Nature Biotechnology

IS - 11

ER -

Engineered human hepatocyte organoids enable CRISPR-based target discovery and drug screening for steatosis

Abstract

Keywords

Access to Document

Fingerprint

Cite this